Skip to search formSkip to main contentSkip to account menu

PI3K Inhibitor GDC-0084

Known as: GDC-0084, GDC0084 
A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Purpose: GDC-0084 is an oral, brain-penetrant small-molecule inhibitor of PI3K and mTOR. A first-in-human, phase I study was… 
2020
2020
Purpose: GDC-0084 is an oral, brain-penetrant small-molecule inhibitor of PI3K and mTOR. Because these two targets alter tumor… 
2019
2019
Purpose: Previous studies have shown that the PI3K/Akt/mTOR pathway is activated in up to 70% of breast cancer brain metastases… 
2019
2019
BACKGROUND: Diffuse Intrinsic Pontine Glioma (DIPG) is a devastating, incurable childhood brain cancer. 80% of patients harbour… 
2018
2018
2018
2018
Glioblastoma is the most aggressive primary malignant brain tumor with few effective therapies. The current study evaluated… 
Highly Cited
2016
Highly Cited
2016
Inhibition of phosphoinositide 3-kinase (PI3K) signaling is an appealing approach to treat brain tumors, especially glioblastoma… 
2016
2016
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Limited treatment options have only marginally… 
2016
2016
2012Background: GDC-0084 is a potent, oral, selective, brain-penetrant small molecule inhibitor of phosphoinositide 3-kinase…